Speaker 1: Welcome to the ASHPOfficial Podcast, your guide to issues related to medication  use, public health, and the profession of pharmacy.
Paige Carson:
Thank you for joining us for the Therapeutics  Thursdays Ambulatory Care Pharmacy podcast. This podcast is hosted by the ASHP  section of Ambulatory Care Practitioners and provides updates on hot topics in  AmCare pharmacy practice. My name is Paige Carson, and I am your host. I work  with the population health group at Atrium Health, which we call ambulatory  care management. And we have eight regional population health teams consisting  of pharmacists, nurse care managers, and health advocates. And we spend at  least 75% of our time working with diabetes patients.
Paige Carson:
With me today are Diana Isaacs from the  Cleveland Clinic Diabetes Center. She is an endocrinology clinical specialist  and CGM program coordinator. We also have Jacqueline Hagarty or Jackie from  Banner University Medical Diabetes and Endocrinology Institute in Phoenix,  Arizona. Thank you for joining us today, Diana and Jackie. And let's get  started talking about today's topic, which is the second CGM podcast in this  series. And the title is Continuous Glucose Monitors and Ambulatory Care  Pharmacy Practice Billing and Clinical Success Stories. So, our first question  for our panel today is to describe how CGMs are presently used in your clinical  practice setting. And we'll start with you, Diana.
Diana Isaacs:
Yeah. Sure. So, we use CGM a whole lot. We  have a really robust shared medical appointment program, where we utilize  professional CGM and that's the type that's owned by the clinic and lent out to  a person for typically 7 to 14 days. And we do them in seven day intervals,  where we have a part one where we put the devices on people and teach about  glycemic targets. And then, we bring people back a week later and review the  data together. We've also expanded to do that for personal CGM as well. So, we  have a start class for people that are starting the same type of CGM. And then,  we also will bring them back, typically after 7 to 14 days, to review what the  data meant and any troubleshooting with that. In addition, we actually also  have a remote monitoring coordinator now who has been following up with  patients who are wearing personal CGMs for more long-term type of management.  Those are just some of the ways we utilize them in our practice.
Jackie Hagarty:
And this is Jackie. Similarly, for us, we use  CGMs mostly on a personal basis. So in other words, an individual CGM that the  patient owns, we have to get it through their insurance and they use it for  self management. And then of course, we use that to make adjustments to their  therapy. So we mainly focus on the personal CGMs rather than utilizing the  professional CGMs. The providers will start them in clinic and then patients  can seek out training on their own or else I, as the pharmacist, or else our  fellow CDEs, which we have a nurse practitioner and a dietician also on our  team, we will also do individual trainings for patients to get started on a  personal CGM.
Paige Carson:
Great. And I have some comments here that you  guys sometimes use shared medical appointments. Can you elaborate more on  those?
Diana Isaacs:
Yeah. So I, in my practice, so typically I, as  a pharmacist, serve as the provider and through collaborative practice  agreements can make medication adjustments. And I do this in conjunction with a  diabetes educator that's usually a nurse or a dietician. We lead the class and  there are usually four to six patients. And then I utilize students to be my  scribes and they chart in the back of the classroom. And it works really well  having multiple people together because what we found, especially when going  through the data is there's a lot of similarities. For example, it's notorious  the American breakfast of cereal or oatmeal often causes spikes in blood sugar  that go way beyond the target of 180. And so those are things you can talk  about together. And we talk about how adding protein at breakfast time can help  prevent it from spiking up quite as fast. Also brings into good discussion  about dosing insulin, how dosing it before the meal can prevent spikes.
Diana Isaacs:
So there's a lot of similarities between  reports that as a group we can discuss together. Another example is I had a  person that was really maxed out on all types of oral and non-insulin  medications like a GLP-1 SGLT2 inhibitor, Metformin, and just glucose was still  running high. And it was clearly insulin was going to be a good next thing to  add, but the patient was really reluctant. And then through seeing his CGM  report and seeing that he actually really was spiking up pretty high in between  meals and overnight, and then just talking to other people in the shared  medical appointment who were already taking insulin and who were able to say,  hey, it's really not a big deal and I feel a lot better because now my blood  sugars are at target. That was able to help the person make the decision that  it was the right thing to do to start, and he ended up doing a whole lot better  and was able to reach his glycemic target. So I think the shared medical  appointments are a really great model to use this technology.
Paige Carson:
Great. That's helpful. And can one of you guys  also comment on how often you would perform remote monitoring for those  patients on CGM, whether that's in the beginning or later on?
Diana Isaacs:
So I think that can be really individualized.  I know, in our program, typically we start someone on the device and we want to  follow up generally in about seven days. And to build the codes there are  certain requirements that you do need to meet in a certain amount of time you  need to be reviewing the data. It depends which code you're actually billing  because if you're doing the CGM interpretation, like the 95251 that you can  only bill once a month, but a person may need more frequent touch points on  that versus if you're using the remote monitoring code. Those are a little bit  different and require a certain amount of time spent per week reviewing the data  so it really varies. We're doing a combination of both right now as we're still  getting used to the new remote monitoring codes. But I would say it's just  really individualized. In the beginning, I like to follow up with someone more  often, and then as they're getting more stable, I think once a month is fine.  And some people even can go to once every three months. [crosstalk 00:06:41].
Paige Carson:
That's helpful.
Jackie Hagarty:
Yeah. I have to agree with that. We would  individualize it based on however you would follow up with a patient, whether  they're on a CGM or self monitored blood sugar, just if they're checking their  blood glucose just a few times a day. If they need medication adjustments, you  want to follow up on that sooner rather than later.
Paige Carson:
Great. Thank you guys for spelling that out.  So what metrics do you use to measure the impact of CGMs?
Jackie Hagarty:
In order to measure the impact of continuous  glucose monitors, we look at quite a few different variables. So the first  thing we look at is within the CGM report itself. After a patient's been  wearing either professional or a personal CGM, you'll get a report on what  their blood sugars are doing so we look at time and range, which for most  patients means in between blood sugar of 70 to 180. We look at percent  hypoglycemia, so in other words, what percent of the time that they spend below  70% hyperglycemia, which, again, for most patients is going to be percent of  the time that they're spend above glucose of 180. Coefficient of variation,  which tells us how variable are their blood sugars. Is it stable? Or is it  really up and down all throughout the day or throughout the week?
Jackie Hagarty:
We also look at the glucose management  indicator, which is similar to A1C in that it gives you a sense of their  overall glucose or glycemic control over the past couple of weeks or whatever  time period you're looking at the report, typically seven to 14 days. And then  another important aspect to look at when you're considering all of these  variables is percent sensor wear, so are they wearing the sensor only 30% of  the time? And then we should take this data with a grain of salt? Or are they  really wearing it 80 to 90%, which would be about our target? In other words,  they're wearing the sensor most of the time throughout the day.
Diana Isaacs:
Yeah. And just to add to that. So data  sufficiency, it's recommended to be at least 70% over a 14 day period. And that  just allows these different statistics, things like the GMI and the coefficient  of variation, to have more meaning. I still think even if you don't have all of  that data, you can still... Let's say you just had the person's last two or  three days. That can still be very valuable and you can walk through what a  person ate and what their day was like, their physical activity level, and you  can still learn a lot. It's just to make these specific terms more meaningful.  Having that amount of data is very helpful. And then a common question I get  is, well, why wouldn't someone have a hundred percent sensor wear? Why wouldn't  they have all that data sufficiency?
Diana Isaacs:
There's a few reasons why someone might not.  So, for example, with the Freestyle Libre, that specific type of CGM requires a  person to scan it to have data. I can only remember up to eight hours of  information at a time. So let's say a person is sleeping for a long time and  goes 12 hours without scanning. That means there will be a four hour gap in  data. For other types of systems, you need to be within a certain number of  feet of the reader or the receiver. And so if a person is out of that range,  that can cause a loss of signal. And also all these sensors require them to be  changed out somewhere between seven and 14 days. And there's a warmup period  every time it's changed or let's say a person just took it off and didn't put a  new one on right away.
Diana Isaacs:
So for all those reasons, there could be some  missing data. And that's why I think as great as time and range is, and I love  time and range, I think A1C, we still do utilize it in practice just because  that's been our gold standard for so long. And if you are missing these gaps or  you do have these gaps in data, at least you still have the A1C to fall back  on.
Paige Carson:
Great. And I know that one of you also  commented that you use a survey to measure the diabetes self-efficacy. Can you  talk a little bit more about that?
Diana Isaacs:
Yeah. So with our CGM shared medical  appointment model, one of the ways we assessed it in addition to A1C was self efficacy.  And this is basically a validated tool that asks questions about certain  behaviors, like comfort in treating hypoglycemia, or the ability to eat at  regular meal times, or how to incorporate physical activity without  experiencing hypoglycemia. And so we did a pre and post survey after attending  the CGM shared medical appointment and afterwords, and showed a pretty big  improvement in self efficacy. And so that's just an indicator that that would  improve diabetes self management, and hopefully also have improvements, or  ultimately lead to improvements in glycemic targets, as well.
Paige Carson:
And tell me how CGM use has impacted patient  satisfaction and also provider satisfaction.
Jackie Hagarty:
Sure. Our patients really love the CGMs for  the most part, and I think the only hangup would be if they have trouble  applying the sensors, or if there's a sensor error, what do they do? But  usually after the first couple times of applying the sensor on their own, then  they're really happy with how it's working. It gives patients a lot of good  feedback. I think, just as Diana mentioned, really using the information or the  data, the metrics that we get to show the patient here's, what's working,  here's what's not working. Can we link up what's happening to your blood sugars  to what's happening on your daily routine?
Jackie Hagarty:
That's really eyeopening for patients more so  than maybe when they're just checking their finger sticks once or twice a day.  So the CGM really improves the patient's self-awareness. A lot of people like  the ease of use and that the CGM can really replace those finger sticks. A lot  of people complain it's painful. It's a huge barrier to carry around all of  your testing supplies all of the time to have to check your blood sugars one to  six times a day. And even six times a day it still isn't giving us all of the  information that a CGM can give us.
Diana Isaacs:
Yeah. My patients just love it. I mean, I feel  like I get the warm fuzzies every day. Because I get to start so many people on  CGM and they're like, thank you. Thank you. This has changed my life. This has  been incredible. And just for some of the points like Jacqueline mentioned  about not having to do the finger sticks all the time, I think that in itself  is huge. But also this idea of having... With a finger stick, you just have one  point in time. So let's say it says 150. Okay? So 150 with two arrows going  down indicating that someone could be crashing within the next half hour versus  a steady 150 are two completely different things. And you don't know that with  a finger stick unless you compulsively recheck your finger stick every couple  of minutes. So to have that type of information at your fingertips, I think it  really is incredible.
Diana Isaacs:
And then on top of that, with many of the  devices being able to have the alerts, it just gives people the confidence to  do things, to be able to go out for that walk, or exercise, or whatever, or get  a good night's sleep because they know if they go low that they have this device  that's going to beep and alert with them. And then on top of that, the ability  to share data with loved ones or other people in their lives, to just have that  extra comfort that knowing that someone else can see what's going on. Let's  say, if something terrible were to happen and they passed out. Someone else is  looking at that data and can call 911, even if they're not with them. So I  think just for all those reasons, I've just been such a cheerleader of this  technology because I have seen firsthand how much it improves people's lives.
Jackie Hagarty:
Yeah. I wholeheartedly agree. And just to add  on another quick example, I have a patient who had type one diabetes and really  variable glucose, even on a CGM. It still didn't really quite help us to stabilize  out her blood sugars. But using the CGM, we're able to do some advanced self  management techniques. So this is not something I go for for everybody. But for  some of my patients who still have really variable blood sugars, we use the  arrows to adjust their correction factor. So in other words, the arrows, if  it's one up arrow or two up arrows, depending on which CGM you're using, it can  tell you how quickly the blood sugar is rising or how quickly it's dropping.
Jackie Hagarty:
So she could add or subtract units of  correction to her bolus insulin dosing, which was really helpful for her. And  that really helped her to gain better control of her diabetes compared to if we  were just making corrections on that one point in time, the here and now  where's her blood sugar at before the meal. Instead, we can see, well where's  the blood sugar going to be at in the next 30 minutes and then make correction  adjustments based on that. And that's made a huge difference for her.
Diana Isaacs:
Yeah. That's really great. And I would just  like to add talking about provider satisfaction because I think this is a mixed  bag. I mean, if you ask me, I love it and I like having the extra information.  I think it's easier to make adjustments to therapy. Not every provider loves it.  And the reason why is because it's something new and in terms of downloading  the data, sometimes it's confusing if you're not used to how to download it.  For example, when devices started switching to smartphones where people could  view it on their phone, immediately our clinic, the people doing intake did not  understand how to download it because it wasn't as simple as just plugging in  the phone.
Diana Isaacs:
You had to go through a separate system. I  think hurdles like that can be alleviated through having a technology expert on  the team who can pay attention to these new things happening and make sure that  the clinic has the right process. Because if you don't know how to download or  look at the data, it can actually be very overwhelming. And when we first  started printing out reports, our MAs were printing out 60 pages, which you can  imagine if you have a 20 minute visit, 60 pages of data is not going to make a  provider happy. So I think there's some steps to work through, but if you can  work through those steps, then you will get providers satisfaction.
Paige Carson:
Great. So have you been able to add additional  pharmacists to your team or FTEs because of the value and the use of CGM?
Diana Isaacs:
So I am so happy to report that yes. We are  hopefully going to be making an offer very soon. We've been interviewing. We  put in a business proposal to have an additional FTE and really the income  generated from professional and personal CGM insertions and interpretations is  where most of that money came from to justify that additional FTE. So I am  thrilled about that.
Paige Carson:
Wonderful. And I can see the need to continue  to grow for a lot of practices. Can you both provide insight on how pharmacists  can successfully bill for CGM services?
Diana Isaacs:
Yes. There's three CPT codes. The CPT 95249 is  for personal CGM starts. This can only be billed once in the life of a device  so that is important to know. And when you do the education and training for  someone starting a new device, this code can be billed. One of the caveats is  you need a download of data of at least 72 hours. So typically I will bring  people back for a follow up visit. And then at that visit bill, because now  I've got the 72 hours of data. In addition to that, there is a 95250, which is  for professional CGM insertion, and download. And so as part of our CGM shared  medical appointments, that's the code that we're billing. And then in addition  to that, there's the 95251, which is for CGM interpretation. Now this code can  go with the professional CGM or with personal CGM and then different insurance  companies have different, I guess, variances in how often they cover it.
Diana Isaacs:
I've seen anywhere from once a month up to  twice a year. One of the very interesting things is with professional CGM, the  coverage is phenomenal. I mean, I would say 99% plus are approved for  professional CGM at least twice a year. And I'm talking these are people that  may not be taking any medications for diabetes, or maybe only taking Metformin,  so the coverage is incredible. Now for personal CGM, the coverage varies  certainly a lot more, so not everyone's going to have access to a personal CGM  device, but it's improved a lot in recent years. We know now Medicare covers  for type one and type two diabetes taking multiple daily injections of insulin,  so definitely a lot more access. And so we have a lot of patients on it. And so  I've been able to bill for these services. Now with the interpretation, one of  the things to know is that Medicare specifies physicians, nurse practitioner,  or a physician assistant.
Diana Isaacs:
They do not say pharmacists, which is  unfortunate. Within the state that I practice, in Ohio, pharmacists are able to  do this. We've checked with our state board. We have provider status. We have  collaborative practice. But to get around this lack of being able to bill, I  have my notes co-signed and generally bill under the ordering provider of the  service. So that's worked well because the money is still coming back to the  clinic. And interestingly the 95250 code for professional CGM is actually  reimburses at a much higher rate than this interpretation, which is often a  pretty low rate. So it tends to work out well. And you could imagine with a  shared medical appointment with five or six people, the amount per person that  you're often taking in could be around $300 for this two part visit. So the  revenue can definitely add up.
Paige Carson:
And when you have the shared medical  appointment, how many patients are you typically bringing in at a time?
Diana Isaacs:
Usually four to six. That's my happy, sweet  spot.
Paige Carson:
Okay. And so just to recap, professional CGM  seems to be much more financially viable if the practice has purchased these  monitors. Right?
Diana Isaacs:
Right. So professional CGM is definitely going  to increase revenue much more than personal CGM. Because personal CGM, you can  only build a 95249 once. The 95251, you can bill ongoing, but that code is a  little bit less. It pays up to $89, but often it could be $40. It just depends  on the insurance plan. But one of the things that I've done is our practice was  not capitalizing on the CGM interpretation. So we were basically losing money.
Diana Isaacs:
I mean, even if it's only $40, we were not  billing it at all. So what I've actually gone in to do is I've had our MAs when  patients come download the data, take a snapshot, and put it into the patient's  chart. We have a smart phrase that I can get routed to me. And then I go back  in and I do these interpretations, which I can do pretty quickly. So that way,  let's say we saw 50 patients that day. I can go in and make sure that those  interpretations done. And so you've got 50 times 40. We can at least get back  some of that revenue. That can be $2,000. And my vision is that we have  residents and students help staffing this to complete the interpretation. So  even though it's not a huge amount of money per person, it really adds up when  you have that kind of volume.
Paige Carson:
That's helpful. So let's talk about barriers  to billing for professional and personal. Can you guys elaborate more on that?
Diana Isaacs:
Yeah. So I think the barrier that I just  mentioned about the interpretation and how it calls out NP physician and PA is  unfortunate with Medicare. And so it does create some hurdles in that we can't  directly bill for that. And we have to have a collaboration with our team,  which I think is actually okay. Because I think diabetes care works much better  as a team, but that means you have to have those arrangements in advance. Also  for the 95249 having to have the 72 hours of data sometimes people don't  realize that and try to bill for it and then end up not getting the  reimbursement because they didn't have that data. And then I would say a third  thing is even though the coverage, especially for professional CGM, is so good,  we're fortunate that we do have someone that checks insurance first because  every once in a while, you might have one that requires a prior authorization.  And the last thing you want to do is bring a patient in and then slap them with  a $400 bill. So those are some of the things that we do.
Paige Carson:
And can you all comment on maybe time or  scheduling?
Diana Isaacs:
Yeah. So I think definitely, I would say one  of the barriers to CGM interpretation and why we weren't billing is just the  time that it takes. The logistics of what you need in the chart and making sure  you've got that image pasted into your electronic medical record, and you're  going through and finishing that interpretation. And so I think that's why we  were leaving a lot of money on the table and our providers weren't finishing it  and we weren't billing for it. The second caveat is some patients will have a  copay when you bill for CGM interpretation. And so they may not love that. And  so you may, if that's something new that you're going to be doing, you have to  let your patients know that I think it's like reading an EKG. We're doing the  work. We're spending the time to do that. We really should be reimbursed for  it, but if someone's been getting something for free for so long, that can be a  big change. If they all of a sudden do get a copay for that.
Jackie Hagarty:
And I'd just like to touch base on some of the  barriers that we've had in really ramping up our professional CGM service or  program at my clinic is definitely the, I guess, fear or concern that some of  our patients have come to have certain expectations regarding office visits and  billing. And if we're suddenly adding additional office visits on top of an  additional service for them that some patients won't want to do that. So I  think the biggest thing is making sure the patients are aware. This is a great  service for you. What will really benefit you in the long run.
Jackie Hagarty:
Educating both the provider's office staff and  the patients on what to expect from a professional CGM service, and that could  help potentially to prevent them from being upset, I guess, about a surprise  bill. Something else would be if you have a pharmacist in the clinic to have  them taking full responsibility for the entire program, as far as making sure  that patients are able to get scheduled for starting up a CGM and then taking  it off, having the report interpreted to make sure that patients don't just get  lost in the general mix.
Jackie Hagarty:
Sometimes that can happen with especially  staffing shortages at a clinic. That's one of the reasons why we were having  problems maintaining a professional CGM service is that patients just wouldn't  return to clinic with maybe some piece of equipment that the clinic had owned.  And then you lose out on both the billing and then any expense that you had  with clinic equipment. So it sounds like Diana's service where the pharmacist  is more in charge of professional CGM using other clinic staff or other  resources maybe, but having that pharmacist or that one centralized person or  team oversight to see the whole program probably really helps to coordinate  everything.
Paige Carson:
Yeah. There's a lot of things to consider. So  would you like to share a patient story related to success with the CGM?
Diana Isaacs:
Sure. So one that stands out to me is I had a  24 year old with type one diabetes who was really checking... I don't know  actually how much he was checking his blood sugars because he never brought in  his meter at all. So his A1C was around 6.7%. I mean, the team was pretty happy  with how he was doing. Prior to this his insulin doses kept being increased and  increased because he had a higher A1C, in the eights and nines. And so the  thought was, oh, he needs more and more insulin. We started with a professional  CGM, so he could see what it was like wearing it. And it turned out that he was  actually experiencing hypoglycemia with a glucose under 70 25% of the time. And  then he was experiencing hyperglycemia over 180 also a pretty significant  amount of time.
Diana Isaacs:
And his glucose variability was really high.  He was going up and down, up and down. So this really showcases how A1C is  limited in that it's an average. And so his average was okay, but he was really  not doing great because he was bouncing around all the time. And so we learned  some pretty valuable things by talking through the data together. As it turned  out, he was on an insulin [inaudible 00:27:27] twice a day regimen. And he was  actually missing that second dose at least half of the time. But it wasn't  because he was a noncompliant or nonadherent patient. It was because he was  experiencing a ton of hypoglycemia and he was probably prescribed way more than  he needed. So by wearing this, I was able to adjust his insulin. I like to  describe as redesign his insulin regimen so it worked better for him. And  ultimately we were able to get him on a personal CGM. So that was very happy  with how that turned out.
Jackie Hagarty:
I also had a really meaningful patient  experience. I had a 22 year old who has type one diabetes and I'd been  following with her for at least six months on adjusting her insulin doses,  trying to work with her on her glycemic control. Similar to Diana's patient,  her A1C was around the 8%, not really budging. Over the course of about six  months, we had tripled her insulin doses with hardly any change in her blood  sugars. We were trying to get her on a CGM, but we had some struggles there  trying to figure out which one is covered by her insurance and how to get it  covered. When we were finally able to start her on a CGM, we quickly realized  that the very first visit when I saw her back, I could visibly see her blood  sugars rapidly increasing. And then it would tell me when she checked her blood  sugar.
Jackie Hagarty:
Okay. That was after she already had an  increase in blood sugar. So despite telling me that she had been compliant,  checking her blood sugar before the meals, and giving her Humalog before the  meals, the CGM actually showed a different story. So I was able to use that  with her and have her visually see what was going on and determine that she was  actually checking her blood sugar after she was eating. So, again, we were able  to back down on the insulin doses so that she wouldn't have hypoglycemia. And  then another thing that it improved for her was it improved her adherence to  her long acting insulin. So she was skipping her long acting insulin at night  if her blood sugar was normal at bedtime because she assumed that she would go  low. So this made her feel so much more comfortable and so much more at ease  that, okay, I'm going to have an alarm or something that's going to wake me up  if I do start to go low.
Jackie Hagarty:
Again, we went over the data together. I  showed her what her blood sugar was actually doing throughout the night. And  she could see, okay, it's stable when I get my long acting insulin. And when I  don't get my insulin, it's just going up throughout the night, which starts my  day off on a bad note in the first place. And I'm having to give more  correction and we're just chasing our tails. So this really was a good patient  education tool, but then also made the patient just feel much more comfortable.  So she's done a lot better ever since getting on her own personal CGM.
Paige Carson:
This is helpful. I think so many of these  patients just were missing out all that variability that you're getting with  the CGM, the data. And hopefully they're feeling a whole lot better. So what is  the one piece of advice that you'd give to AmCare pharmacists taking to  initiate CGM services or for pharmacists that are seeking to expand their  services to include CGM information?
Diana Isaacs:
Yeah. If you can convince your clinic to  invest in professional CGM, I think that's such a great place to start,  especially because Libre Pro is about $60 per sensor. So it's a really low  investment cost. You need a reader, which is $65. You make it back. I mean, one  patient you've already made a profit. And then Dexcom G6 Pro should be  available very soon and that's going to be also a disposable. Hopefully it's  expected to be a comparable price. So I think that's just such a good way to  start. And I think also working with the reps in your area. And if you don't  know who your rep is for the different CGM companies usually, you can find that  online. And I think they're very helpful. If you get the opportunity to try  wearing one yourself, that's really the best way to learn and it's fascinating.  And that way you can really get used to looking at those reports and  everything. But those I think are great ways to get your feet wet.
Jackie Hagarty:
Yes. I definitely agree with that. I think  those are really good suggestions for any pharmacist looking to get into this  area. And then I think really emphasizing both the patients and providers that  this is a really good patient self management tool. So I think a lot of times  we think of CGM as we get all this data and that's really great for us, but  also seeing that patients, a lot of times, their A1Cs will just improve just by  switching over from finger sticks to a CGM. So realizing that just more  self-awareness, as long as they're being engaged, this can be a really good  tool for them even without making any other adjustments to their medication  regimen.
Jackie Hagarty:
So I think using the CGMs' reports and making  sure that we are sharing those with patients or helping them to understand what  they're really looking at, rather than saying, okay, this is something that we  just put in their chart, but remembering to go over the data in detail at the  patients, I think is really helpful.
Paige Carson:
Thank you. So that's all the time we have  today and I want to thank Dr. Isaacs and Dr. Hagarty for joining us today and  really sharing their experiences to discuss CGMs and AmCare pharmacy practice  and sharing on billing and clinical success stories. Thank you. Join us here  every Thursday where we will be talking with ASHP member content matter experts  on a variety of clinical topics.
Speaker 1: Thank you for listening to ASHPOfficial, the voice of pharmacists  advancing healthcare. Be sure to visit ASHP dot org forward slash podcast to  discover more great episodes, access show notes, and download the episode  transcript. If you love the episode and want to hear more, be sure to  subscribe, rate, or leave a review. Join us next time on ASHPOfficial.